GS 9688

Drug Profile

GS 9688

Alternative Names: GS-9688

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 20 Apr 2017 Phase-I clinical trials in Hepatitis B in New Zealand (PO)
  • 20 Feb 2017 Gilead Sciences plans a phase Ib trial for Hepatitis B in Australia, South Korea and New Zealand (ACTRN12617000235303p)
  • 06 Dec 2016 Preclinical trials in Hepatitis B in New Zealand (PO) (ACTRN12616001646437p) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top